Ms. Sen Wang | Cancer Cell Biology | Best Researcher Award

Ms. Sen Wang , Affiliated Hospital of Jining Medical College , China

Dr. Wang Sen is an accomplished researcher and Deputy Chief Technician at the Affiliated Hospital of Jining Medical University. With a Ph.D. in Pharmaceutical Engineering and a postdoctoral fellowship at Shandong University of Traditional Chinese Medicine, he has developed deep expertise in molecular oncology, tumor microenvironments, and translational medicine. His career spans over a decade, marked by significant research in gastrointestinal and renal cancers, exploring mechanisms of autophagy, endothelial dysfunction, and tumor angiogenesis. Dr. Wang has led and contributed to several prestigious research projects, including National Natural Science Foundation grants. He has published in high-impact journals and holds patents that support translational applications in oncology. Recognized by peers and institutions alike, he received the Shandong Medical Association Youth Science and Technology Award. His work continues to push boundaries in cancer research, demonstrating strong scientific leadership and a commitment to improving therapeutic strategies.

Publication Profile: 

Scopus

✅ Strengths for the Award

1. Extensive Research Background
   Dr. Wang has demonstrated a consistent and deep involvement in cutting-edge cancer research, especially focusing on tumor microenvironment regulation, autophagy, and angiogenesis—key areas in translational oncology.

2. Prolific Publication Record
   He is the sole first author of several papers published in high-impact journals like British Journal of Cancer, Cell Death & Disease, and Scientific Reports. These contributions indicate scientific independence and strong writing and experimental skills.

3. Leadership in Funded Projects
   He has served as Principal Investigator (PI) on multiple prestigious projects, including the NSFC Youth Fund and China Postdoctoral Foundation grants, which testifies to his research leadership and capability in securing competitive funding.

4. Innovative Impact through Patents
   Dr. Wang is a co-inventor of three Chinese patents, including a novel therapeutic application of MT1G in renal cancer—highlighting a strong translational component in his research.

5. Academic Awards and Recognition
   His receipt of the Shandong Medical Association Youth Science and Technology Award (Second Prize) in 2024 is an external validation of his scientific excellence at the provincial level.

6. Collaborative and Interdisciplinary Approach
   His co-authorship with experts across molecular biology, pharmacology, and clinical research demonstrates a collaborative nature crucial for multidisciplinary medical advancements.

📈 Areas for Improvement

1. International Recognition
   While Dr. Wang’s work is commendable within China, increasing collaboration or recognition on an international level (e.g., international conferences, global research networks) would further elevate his research visibility.

2. Citations and Real-world Applications
   Some of his recent papers have not yet garnered citations. Continued dissemination, follow-up studies, and clinical application testing will help boost impact.

3. Expanded Mentorship Role
   There is limited information on his mentorship of young scientists or PhD students. Strengthening academic mentorship could broaden his influence within the scientific community.

🎓 Education:

Dr. Wang Sen has pursued a comprehensive academic path in life sciences and medical research. He earned his Ph.D. in Pharmaceutical Engineering from Chongqing Medical University (2016–2019), following a Master’s degree in Biochemistry and Molecular Biology at the same institution (2013–2016). His foundational training began with a Bachelor’s degree in Biological Engineering from Jining University (2009–2013), where he laid the groundwork for his interest in molecular biology and drug development. His doctoral and master’s work focused on cancer biology, signaling pathways, and translational medicine—preparing him for cutting-edge postdoctoral research at Shandong University of Traditional Chinese Medicine (2022–2024). This academic journey has equipped him with strong theoretical and experimental skills that he applies in both clinical and laboratory settings.

🧪 Experience:

Dr. Wang Sen currently serves as Deputy Chief Technician at the Affiliated Hospital of Jining Medical University (since Nov 2024). Prior to this, he held the role of Chief Technician (2019–2024) at the same hospital, where he led several translational cancer research projects. His responsibilities include designing experimental protocols, overseeing clinical collaboration, and mentoring junior researchers. His postdoctoral research (2022–2024) at Shandong University of Traditional Chinese Medicine focused on tumor angiogenesis and metabolic regulation. Throughout his academic and professional journey, he has shown a keen interest in understanding cancer cell signaling, tumor-endothelial interactions, and the development of therapeutic targets. His multidisciplinary expertise makes him a vital contributor to collaborative projects in molecular medicine and drug discovery.

🏆 Awards and Honors:

Dr. Wang Sen’s contributions to medical research have earned him notable recognition. In 2024, he received the Shandong Medical Association Youth Science and Technology Award (Second Prize), celebrating his innovative work in cancer biology. He is also a co-inventor on three Chinese patents, including the application of MT1G protein inhibitors for renal cancer and methods related to small molecule metabolite ligands and exosome preparation. These patents demonstrate his commitment to translational research and innovation in therapeutic development. Additionally, his participation in collaborative high-impact publications and national grants has solidified his reputation as a rising leader in biomedical sciences. His academic integrity, technical depth, and consistent contributions to cutting-edge research make him an ideal candidate for recognition through prestigious awards like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang Sen’s research centers on tumor microenvironment regulation, angiogenesis, autophagy, and tumor stem cell interactions, with a strong focus on gastrointestinal and renal cancers. His work often integrates cellular signaling, exosome biology, and gene expression regulation to understand cancer progression and metastasis. Key interests include pathways involving INSR/FGF5/ADRB2, ALDOC, and MT1G, which he investigates for their roles in tumor metabolism and vascular dynamics. Dr. Wang combines clinical relevance with basic science, aiming to translate molecular findings into diagnostic tools or therapeutic targets. His innovative studies on betulinic acid, p53-mediated pathways, and epigenetic modifications contribute to the broader field of precision oncology. His interdisciplinary approach—bridging pharmacology, molecular biology, and clinical application—positions him as a dynamic researcher capable of advancing medical science.

📚 Publications Top Notes:

1. 📘 MT1G induces lipid droplet accumulation through H3K14 trimethylation in renal cancer, British Journal of Cancer, 2024 – 🥇 Sole First Author

2. 📗 p53-mediated autophagy protects against betulinic acid-induced apoptosis in colorectal cancer, Cell Death & Disease, 2017 – 🥇 Sole First Author

3. 📕 FOXS1 is regulated by GLI1/miR-125a-5p, promotes proliferation and EMT in gastric cancer, Scientific Reports, 2019 – 🥇 Sole First Author

4. 📙 Identification of the human HAS3 promoter region, Biochemical and Biophysical Research Communications, 2015 – 🥇 Sole First Author

5. 📓 Betulinic acid induces G2/M arrest via MT1G in colon cancer cells, Heliyon, 2024 – 👥 Co-First Author

6. 📔 PCDH17 induces colorectal cancer metastasis by disrupting vascular barriers, Cell Death and Disease, 2025 – 🧬 Contributor

7. 📒 OX40 activation drives tumor escape via S1P/YAP angiogenesis, Journal of Clinical Investigation, 2025 – 🧬 Contributor

🧾 Conclusion:

Dr. Wang Sen is a highly qualified and worthy candidate for the Best Researcher Award. His impressive portfolio—spanning publications, funded projects, patents, and recognized awards—shows that he is not only producing important knowledge but also moving toward real-world application in cancer therapeutics. With continued focus on global engagement and translational outcomes, he is poised to become a leading figure in molecular oncology. His scientific rigor, innovation, and leadership embody the spirit of this award.